Dr. Reddy's Laboratories

₹1,373As of Sun 8 Nov 2026, 12:00 UTC

NSE:DRREDDYHealthcare

Country India

PE (Fwd) 22.33

TSR 10Y CAGR 8.23%

Div yield 0.58%

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.20

PE TTM 26.70

TSR TTM 15.37%

Mkt cap ₹1.149T

ROIC —

SE Grade™

Value

Quality

Moat

—

1Y Price

Reference

₹1,493

8.74%

(39.70%)

Price above Reference Value

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

335.9

Revenue₹B

—

214.4

245.9

279.2

325.5

335.9

363.5

11.88%

3.19

Revenue growth%

—

14.69

13.54

16.61

3.19

8.21

14.11

—

52.77

Gross margin%

—

53.10

56.67

58.61

58.50

52.77

52.88

56.67

14.66

Operating margin%

—

16.75

21.72

23.39

22.12

14.66

14.81

21.72

12.76

Net margin%

—

10.99

18.33

19.95

17.37

12.76

12.98

17.37

26.70

P/E ratio (avg)x

—

34.18

15.98

16.72

18.59

24.13

24.24

18.59

23.23

EV/EBITx

—

22.43

13.48

14.25

14.60

21.00

21.25

14.60

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

51.42

EPS₹

—

28.34

54.17

66.80

67.78

51.42

56.64

16.06%

—

(24.14)

EPS growth%

—

91.16

23.32

1.47

(24.14)

10.15

12.39

—

Bookvalue per sh₹

—

FCF per share₹

—

8.00

Dividend per sh₹

—

6.00

8.00

8.24

7.46%

—

0.58

Div yield (avg)%

—

0.62

0.92

0.72

0.63

0.64

0.60

0.64

15.56

Payout ratio%

—

21.17

14.77

11.98

11.80

15.56

14.56

14.77

833.3

Shares (diluted)M

—

831.7

831.9

833.5

834.2

833.3

◌833.3

0.05%

0.10

Buyback yield%

—

(0.03)

(0.19)

(0.08)

0.10

◌—

(0.05)

—

D/E ratiox

—

1,144

Enterprise value₹B

—

805.5

720.2

930.8

1,051

1,034

1,144

6.44%

—

LT debt₹M

—

Peers (US$12.16B)

Cap (US$)

Zydus Lifesciences…

12.72B

28.64x

Cipla Limited

12.14B

39.36x

Mankind Pharma Limited

11.17B

46.83x

Zhejiang NHU Company…

12.30B

11.24x

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

13.17

37.41

Own earn%

—

Sh yield%

0.68

0.65

Owners

Insiders/Inst%

26.72

57.72

Short interest%

—

SBC / revenue%

0.09

Record

10Y

Profitable years

5/5

Revenue growth years

4/4

EPS growth years

3/4

Dividend streakyrs

Op margin range%

15–23

$1 testx

—

Incr. ROIC%

—

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹335.9B

11.88%

1.00×

Cost of revenue

₹158.7B

12.08%

1.01×

Operating expenses

₹128.0B

13.22%

1.05×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m